Magnetic Resonance-Guided Adaptive Radiotherapy (MRgART) Using an Integrated Magnetic Resonance Linear Accelerator (MRL)

Recruiting

• Conditions: Cancer

• Registration Number: NCT04135794
• Lead Sponsor: University Health Network, Toronto

Brief Summary

This study is being done to help further understand how MR-guided adaptive RT in conjunction with the Integrated Magnetic Resonance Linear Accelerator (MRL) can improve patient outcomes. This study will include participants who will be receiving radiotherapy using the MRL machine to target their cancer more precisely. Participants will be asked to have a few extra MR scans taken during their RT planning and to complete a few quality of life questionnaires.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-10-15
• Study First Submitted QC: 2019-10-20
• Study First Posted: 2019-10-23
• Study Start: 2019-12-09
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-17
• Last Update Posted: 2024-06-18
• Primary Completion: 2026-11-30
• Study Completion: 2026-11-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Patients 18 years or older with a diagnosis of cancer, regardless of clinical site or stage
• Planned to receive a course of MR-guided adaptive RT using the MRL
• Ability to provide informed consent

Read More

Exclusion Criteria

• Patients under 18 years old

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Complication rates measured using the Common Toxicity Criteria for Adverse Events	Within 3 months of completing treatment	Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.
Local, regional and distant tumor control rates	Up to 5 years post-radiotherapy	Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.
Disease-free and overall survival rates	Up to 5 years post-radiotherapy	Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.

Secondary Outcome Measures

Name	Time	Method
Patient experience and anxiety related to MR imaging and adaptive RT with the MR	each ambulatory care and radiation treatment review clinic visit (up to 5 years post treatment)	Evaluate the patient experience during adaptive RT with the MRL using complete the Edmonton Symptom Assessment Scale revised version (ESAS-r)

Trial Locations

Locations (1)

Princess Margaret Cancer Centre; 🇨🇦 Toronto, Ontario, Canada